Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Merck
Medtronic
Express Scripts
Dow

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Nimotuzumab

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Nimotuzumab: Patents, clinical trial progress, indications

Nimotuzumab is an investigational drug.

There have been 67 clinical trials for Nimotuzumab. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2016.

The most common disease conditions in clinical trials are Carcinoma, Esophageal Neoplasms, and Carcinoma, Squamous Cell. The leading clinical trial sponsors are Biotech Pharmaceutical Co., Ltd., Peking University, and Chinese Academy of Medical Sciences.

There are fifty-nine US patents protecting this investigational drug and nine hundred and nine international patents.

Recent Clinical Trials for Nimotuzumab
TitleSponsorPhase
Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell CarcinomaThe First Affiliated Hospital of Zhengzhou UniversityPhase 2
Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal CarcinomaChinese Academy of Medical SciencesPhase 2
Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal CarcinomaAffiliated Cancer Hospital & Institute of Guangzhou Medical UniversityPhase 3

See all Nimotuzumab clinical trials

Clinical Trial Summary for Nimotuzumab

Top disease conditions for Nimotuzumab
Top clinical trial sponsors for Nimotuzumab

See all Nimotuzumab clinical trials

US Patents for Nimotuzumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Nimotuzumab   Start Trial Binding molecules specific for HER3 and uses thereof MEDIMMUNE, LLC (Gaithersburg, MD)   Start Trial
Nimotuzumab   Start Trial Multispecific constructs AbbVie Stemcentrx LLC (North Chicago, IL)   Start Trial
Nimotuzumab   Start Trial Anti-EGFR activatable antibodies CytomX Therapeutics, Inc. (South San Francisco, CA)   Start Trial
Nimotuzumab   Start Trial Substituted urea derivatives and pharmaceutical uses thereof SUNSHINE LAKE PHARMA CO., LTD. (Dongguan, Guangdong, CN)   Start Trial
Nimotuzumab   Start Trial Azabicyclo derivatives, process for preparation thereof and medical use thereof Shanghai Haiyan Pharmaceutical Technology Co., Ltd. (Shanghai, CN) Yangtze River Pharmaceutical Group Co., Ltd. (Jiangsu, CN)   Start Trial
Nimotuzumab   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Nimotuzumab

Drugname Country Document Number Estimated Expiration Related US Patent
Nimotuzumab Australia 2012340766 2031-11-23   Start Trial
Nimotuzumab Brazil 112014012539 2031-11-23   Start Trial
Nimotuzumab Canada 2856297 2031-11-23   Start Trial
Nimotuzumab China 104093743 2031-11-23   Start Trial
Nimotuzumab China 108424456 2031-11-23   Start Trial
Nimotuzumab Colombia 7051008 2031-11-23   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Johnson and Johnson
Merck
Express Scripts
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.